Novartis Acquires SanReno Therapeutics, a Shanghai Company with Two IgAN Candidates

Novartis acquired the 50% of Shanghai’s SanReno Therapeutics it didn’t already own from the consortium of investors who helped to found the company in 2021. SanReno, a company developing two late-stage therapies for Immunoglobulin A Nephropathy (IgAN), was formed by Seattle’s Chinook Therapeutics in late 2021 to bring its kidney disease drug candidates to China and Singapore. Chinook, which owned 50% of SanReno, was acquired by Novartis in a $3.5 billion agreement in June of last year. The remaining 50% belonged to SanReno’s founding investors: Pivotal bioVenture Partners China, Frazier Life Sciences, Samsara BioCapital, and Versant Ventures, who capitalized SanReno with an original $40 million round. More details....

Share this with colleagues: